TSXV · GSD.V
Devonian Health Group, Inc.
CA$7.50+CA$0.75 (+11.11%)
Devonian Health Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
Loading market information…
OTC · NYMXF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nymox Pharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 84.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nymox Pharmaceutical Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma. Beyond its drug pipeline, Nymox develops and offers two diagnostic products: NicAlert, which identifies tobacco usage, and TobacAlert, designed to detect exposure to secondhand smoke. The company is also actively engaged in developing treatments for Alzheimer's disease. Nymox Pharmaceutical Corporation was established in 1989 and maintains its headquarters in Nassau, the Bahamas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:18 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$7.50+CA$0.75 (+11.11%)
Devonian Health Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$1.15$0.00 (0.0%)
HOOKIPA Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.81% below the high.
A$0.01A$0.00 (0.0%)
Algorae Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
$0.07-$0.02 (-18.75%)
Inhibitor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.58% below the high.
$0.02-$0.00 (-1.32%)
ALR Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.78% below the high.
$0.08$0.00 (0.0%)
EOM Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.22% below the high.
CA$0.06CA$0.00 (0.0%)
Hemostemix Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.45% below the high.
£0.00+£0.00 (+9.0%)
Oxford BioDynamics Plc’s quoted price sits in the lower half of its reported 52-week range, 66.18% below the high.
